Glenrothes' New Release Is Delicious, Affordable And A Surprise Move
Courtesy: Glenrothes
After a relatively prosperous era of expansion, the Scotch whisky category is showing signs of strain. According to the Scotch Whisky Association, export volumes dropped nearly 9.5% in 2023, even though total sales remained roughly the same. Similar trends have been reported in the U.S., with the Distilled Spirits Council (DISCUS) reporting a 17.4% drop in volume from 2019 to 2024.
That same report shows that the only growth category by revenue has been 'super premium,' For a long time, a go-to strategy has been a tilt toward even more high-end offerings: premiumization. Higher age statements, boutique packaging, and collector-geared bottlings became the norm. Just last month, Tamdhu released a 43-year-old expression priced at $16,000 and Johnnie Walker launched the first releases from its much-hyped Johnnie Walker Vault.
But in 2025, economic caution is setting in and consumer spend is flattening. RBC analysts focusing on Diageo (which owns Johnnie Walker, Talisker and Lagavulin, among others) said late last year that they 'estimate that the proportion of sales from high-end reserve brands fell from 29% in 2023 to 27% in 2024.' That's on top on-and-off tariffs threatening massive price swings and availability issues for consumers. Amid all that uncertainty, there's an opening for contrarian moves.
That's the market context surrounding the release of The Glenrothes The 15, a new permanent addition to the Speyside distillery's portfolio. Now available across the U.S, The 15 comes in with an age statement below their flagship 18 and 25-year-old expressions (not to mention their very, very premium 42-year-old option). Moving to a lower age statement seems like a broad against premiumization—though it's not entirely so simple.
First off, at $100 SRP, this Single Malt certainly hasn't entered the 'value' category. With 100% first-fill European oak sherry casks, upscale packaging, and a complex flavor profile, The 15 is designed to hit a balancing point: accessible yet still prestige.
Laura Rampling, The Glenrothes' Master Whisky Maker, describes the spirit in a statement as "a counterintuitive marriage of the delicate and the bold," bringing sweet fruit and bright spice into a bold but balanced profile. It finishes rich, silky, and spice-laced, an excellent example of the Speyside style and a very sessionable sipper in general.
The Glenrothes, long considered a hidden gem in Speyside, has built a quiet legacy since 1879 with its slow distillation and emphasis on high-quality oak. The release of The 15 underscores its confidence in those fundamentals. Where some competitors are trimming SKUs or maintaining a slate of ultra-limited releases, The Glenrothes is reinforcing its house style while also onboarding a more affordable age statement.
The Glenrothes The 15 marks a shift in the age-statements that the distillery offers.
Courtesy: The Glenrothes
In a tightening market, The Glenrothes The 15 isn't just a new bottle, it's a signal that brands can't count on premiumization forever. That's not to say that brands won't still release ultra-premium expressions.
Instead, if The 15 shows signs of success, there could be an opening for brands with a willingness to carry their upscale products to a more accessible point in the market. It could also answer signal a new trend: premiumization that goes both ways.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Gatwick passengers warned of severe August delays amid baggage screener strike
Holidaymakers flying from Gatwick Airport could face severe delays as baggage screeners prepare to strike over pay, the UK's largest union has warned. The walkout, set for later this month and covering the August bank holiday, is expected to disrupt travel for thousands of passengers. Baggage screeners will strike from August 22 to August 26 and from August 29 to September 2, Unite the Union has said. All flights out of Gatwick will face disruption during these times, the union said, warning industrial action will intensify if the dispute is not resolved. Unite general secretary Sharon Graham said'ICTS has more than enough money to offer these workers a fair pay rise. Not doing so is just corporate greed. 'ICTS' Gatwick workers will receive Unite's complete backing for as long as it takes during their strikes for fair pay.' Unite has said workers, employed by ICTS, are amongst the lowest paid workers at the airport and earn just above the minimum wage. Despite this, ICTS's turnover has grown by 110 per cent since 2020, reaching £170.59 million in 2024, the union said. It made a profit before tax of £6.1 million in 2024, a 46.9 per cent increase compared to the year before. Unite regional officer Ben Davis said: 'ICTS is entirely responsible for the disruption that will be caused to Gatwick passengers during the strike action. It can well afford to put forward an acceptable pay offer and that is what needs to happen. 'Despite performing a critical role, these workers are amongst the lowest paid at the airport. Gatwick should be stepping in and pressuring ICTS to put an improved offer forward.' A spokesperson for Gatwick said the airport does not anticipate significant disruption if strikes were to go ahead. They said: 'We are working with our suppliers to avoid any impacts and we expect to operate a normal summer holiday flight schedule for our airlines and passengers on these dates. Of course, we hope ICTS and their union can reach a resolution before then.' ICTS has been contacted by The Standard for comment.
Condé Nast Traveler
20 minutes ago
- Condé Nast Traveler
Inside the Leather Workshops of Andalusia
Menacho opened his workshop in the whitewashed village of Castilblanco de los Arroyos, a 45-minute drive north of Seville, a decade ago—but had never planned to work with leather. A keen equestrian, he wanted to become a riding instructor but failed the entrance exam. 'The following week they called me to see if I wanted to join the saddlery course instead,' he says. 'I said yes because I'd always enjoyed working with my hands. I learned cutting and stitching, how to differentiate between leather types, and how to make basic riding bags,' he says. It was through making saddles, tack, and other equestrian items, that he acquired the techniques that would make him a leading leathermaker in Spain—and across the fashion world. But the craft, and the ancient artisanal methods he follows, holds a deep significance for Menacho. Leatherwork in Andalusia dates back as far as the Islamic period, when cities like Córdoba became hubs for the trade. 'For me, it's a way of life and a symbol of identity,' he says. This history, and the region's deep connection with horses—as seen through its rich culture of agriculture and equestrianism—has led generations of Sevillian leather workers to hone and evolve the craft. Sacred art related to Seville's Semana Santa Easter festivities is at the root of many artisans' designs, while others are inspired by the city's rich mix of Moorish, Gothic, Mudejar, Renaissance and Baroque architecture. But artisanal work is hard work, and a number of craftspeople are beginning to rely more on machinery than the traditional methods to create their products. Younger generations, meanwhile, are moving away from the professions of their parents to embark on more modern careers. Both are developments that Menacho and many of his peers worry will not only dilute the quality of the product, but this intrinsic part of Andalusian life more deeply, too. 'The work of an artisan is culture, art, and history, but it can also be the future,' he says. 'I try to show people the real value of artisanal work so that we don't lose it.' Menacho, whose workshop is almost entirely free of machinery, does 90% of his work by hand Cristina Gómez Ruiz Techniques done by hand by artisans like Menacho distinguish, in their book, their work from industrial product Cristina Gómez Ruiz Menacho's own leather craft involves chiseling and scoring, die-cutting and stitching, embossing and gilding. He treats his leathers the traditional way with vegetable dyes in oak barrels, a process that can take between six and twelve months. His workshop is practically free of machinery, and 90% of the work he does is by hand, often using techniques that date back centuries, something that Menacho feels distinguishes an artisanal product from something industrial. 'The old, traditional methods are the ones that really work. Some of them date back 500 or 800 years. They're based on time, rhythm, and knowledge of materials,' he says.
Forbes
21 minutes ago
- Forbes
Truckin' To 2030: Europe's Green Horizon For Medical Cannabis & Hemp
Europe's cannabis sector is undergoing a profound transformation—one driven by evolving regulations, changing social attitudes, and rising institutional investor interest. Germany, as the continent's largest economy, stands at the heart of this transition, leading a dual trajectory in both medical cannabis and industrial hemp. What was once niche is now positioned as a cornerstone of sustainable health, clean materials, and innovative investment opportunities. You might say that the European industry appears to be built to last. Market Overview and Segmentation Europe's cannabis landscape is divided into two distinct segments: THC‑containing cannabis (above 0.3% THC), regulated primarily for medical and sometimes adult-use purposes; and industrial hemp (below 0.3% THC), employed in foods, textiles, bioplastics, cosmetics, and construction. While sharing a botanical origin—Cannabis sativa L.—each operates under its own regulatory framework, supply chain, and market focus. Understanding this segmentation is essential for investors and policymakers evaluating risk and opportunity. Globally, the medical cannabis market was valued at approximately €4.5 billion in 2024 and is projected to reach over €62 billion by 2030—recording a staggering compound annual growth rate (CAGR) of 55%. Europe, fueled by demographic shifts and legal liberalization, is forecasted to be the fastest-growing region. Meanwhile, the industrial hemp market is poised to triple to around €15 billion by 2030, according to UNCTAD projections, driven by surging demand for climate-friendly materials and plant-based nutrition. Regulatory Developments The eyes of the world are on Germany, as it has emerged as the regulatory focal point in Europe. Its Cannabis Act (CanG), enacted in 2024, removed restrictive quotas and significantly expanded medical access. A complementary Medical Cannabis Act (MedCanG) is under development, emphasizing pharmacy-based distribution while tightening telemedicine channels. In parallel, a new Industrial Hemp Liberalization Act is expected in 2026, poised to eliminate outdated restrictions and modernize hemp production regulation. On the EU level, the classification of CBD as a Novel Food is opening doors to wellness and nutrition markets previously inaccessible for hemp producers. Growth in Medical Cannabis Since medical cannabis legalization in 2017, German patient numbers have soared—with 300,000 individuals receiving prescriptions in 2024, estimated to grow to 840,000 in 2025. By 2030, the market is expected to reach €650 million. Innovations in formulation—such as high-purity extracts, dronabinol pills, and cannabinoid pastilles—are expanding therapeutic use across neurology, chronic pain, and oncology. Major operators like SYNBIOTIC SE are leading the charge, developing standardized dosage forms and investing in regulated production. Global companies such as Tilray, Aurora, OrganiGram, and Canada's Sanity Group (via its partnership with OrganiGram) are deepening their European presence, underlining the continent's rising magnetism for international cannabis investors. Industrial Hemp as a Sustainability Engine Industrial hemp, long undervalued, is now recognized as a strategic asset in Europe's green economy. German industrial hemp sales grew from €526 million in 2023 to a projected €3 billion by 2032 (CAGR ~22%). Applications range from hemp-protein powders to sustainable building insulation and biodegradable packaging. EU regulatory shifts—especially Novel Food approvals for CBD—further enable consumer-facing products. Companies such as Hempro International and new-era ventures targeting hemp-based construction materials and plant-based supplements illustrate the growing breadth of the market. Investment Opportunities and Strategic Challenges Europe is increasingly attractive to North American capital. SYNBIOTIC SE exemplifies a diversified strategy, combining medical cannabis and hemp under a unified corporate model. The publicly traded holding company expects revenues to climb from €26 million in 2025 to €47 million by 2027, with positive EBITDA forecasted in 2026. This dual exposure provides a hedge against regulatory divergence and price compression in either sector. David Hyde, founder and CEO of Hyde Advisory & Investments, plays a pivotal role in monitoring and facilitating cannabis investments in Germany. Through his firm's expert brokerage services, Hyde navigates complex regulatory frameworks, matches strategic partners, and helps investors identify high-quality medical cannabis assets in the German market. Drawing from his firm's insights, Hyde notes: Germany's medical cannabis market continues to grow, albeit more slowly than Australia's. While German market competition is increasing, there is lots of room for new brand/category entrants with proper market research, understanding of developed cannabis markets and the right distribution partner(s)." Several industry leaders are confident that Europe represents the next major frontier for cannabis investment. As Boris Jordan, Executive Chairman of Curaleaf, put it, '[Europe is the next big market for cannabis after the U.S.]' Meanwhile, Irwin Simon, CEO of Tilray, emphasizes the scale of the opportunity: 'Germany's de-scheduling of cannabis opens the path to new opportunities in a potential $3 billion medical market; the European Union medical cannabis market is now projected to become $45 billion.' Constantin von der Groeben, founder of Demecan, reflects on Germany's growth momentum: 'The market is on a constant growth that is overwhelming,' while Beau Whitney, head economist at Whitney Economics, sees a broader European transformation underway: 'We can expect an accelerated expansion in the EU of legalised cannabis… If countries reform quickly, then the EU could supplant the U.S. as the major leader in global cannabis reform.' Yet investors must navigate risks: regulatory uncertainty (especially around telemedicine and CBD policy), intense price competition as production scales, limited banking integration, and macroeconomic volatility. The fragmented legal landscape further complicates capital deployment in cannabis-related ventures. Why Legalization Is Working The legalization model in Europe—and particularly in Germany—has shown measurable success. Its framework promotes transparency, standards for safety and quality, and integration into conventional health systems. The emphasis on licensing, standardized extracts, and court-regulated pharmacies mirrors a methodical approach, providing market certainty for investors and patients alike. Moreover, reform frameworks that prioritize illicit-market conversion—such as transitioning traditional, unregulated growers into legal cooperatives—mirror best practices championed by analysts like Whitney Economics. This conversion aligns economic incentives, reduces social harms, and demonstrates the sustainability of the legal regime. Outlook to 2030 As of 2025, both medical cannabis and industrial hemp are poised to become multibillion-euro pillars of Europe's economy. By 2030, medical cannabis in Europe could exceed €10 billion, while industrial hemp ascends as an eco-driven mainstay. Companies rooted in innovation, regulatory compliance, and product diversification will lead market consolidation. Germany will remain the driving force behind this evolution—acting as the regulatory pioneer and investment hub for cannabis in Europe. Institutional and private investors seeking long-term value should consider pan-European platforms that bridge both cannabis segments, such as publicly traded SYNBIOTIC SE. Their IFRS-audited integrated model reflects the shift to a new chapter in medicine and an innovative sustainable economy. END NOTES: CanG Gesetz 2024 – UNCTAD 2022 – Cannabissciencetech 2024 – CannaMonitor 2025 – Credence Research – Grand View Research – IMARC Group – Luminorecruit 2025 – MJBizDaily 2024 – Novel Food – OrganiGram/Sanity Group 2024 – Research And Markets 2024 – Reuters 2024 – Statista – Weedman 2025 –
